DFV890 placebo

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Clonal Hematopoiesis of Indeterminate Potential (CHIP)Coronary Heart Disease

Phase 2

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

CompletedNCT06031844

Novartis PharmaceuticalsCoronary Heart Disease

Start: 2023-10-16End: 2024-12-23Updated: 2026-03-27

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

CompletedNCT06097663

Novartis PharmaceuticalsClonal Hematopoiesis of Indeterminate Potential (CHIP), Coronary Heart Disease

Start: 2024-02-15End: 2024-11-04Updated: 2026-03-27